Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity

Hema Adhikari; Walaa E. Kattan; Shivesh Kumar; Pei Zhou; John F. Hancock; Christopher M. Counter

doi:10.1038/s41467-021-25523-5

Nature Communications (Sep 2021)

Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity

Hema Adhikari,
Walaa E. Kattan,
Shivesh Kumar,
Pei Zhou,
John F. Hancock,
Christopher M. Counter

Affiliations

Hema Adhikari: Department of Pharmacology & Cancer Biology, Duke University
Walaa E. Kattan: Integrative Biology & Pharmacology, McGovern Medical School, University of Texas Health Science Center
Shivesh Kumar: Department of Biochemistry, Duke University
Pei Zhou: Department of Biochemistry, Duke University
John F. Hancock: Integrative Biology & Pharmacology, McGovern Medical School, University of Texas Health Science Center
Christopher M. Counter: Department of Pharmacology & Cancer Biology, Duke University

DOI: https://doi.org/10.1038/s41467-021-25523-5
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 21

Abstract

Read online

The lipid composition of the plasma membrane defines the localisation of KRAS and its oncogenic function. Here the authors show that EFR3A binds to active KRAS to recruit PI4KA and alters the lipid composition of the plasma membrane to promote KRAS oncogenic signalling and tumorigenesis.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal